Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study
暂无分享,去创建一个
M. Congreve | F. Marshall | P. Nathan | M. Weir | D. Cross | Alastair J. H. Brown | E. Hart | G. Groeneveld | E. Klaassen | Giles A. Brown | R. Doll | T. Tasker | C. Bakker | J. Liptrot
[1] M. Congreve,et al. First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias , 2020, British journal of clinical pharmacology.
[2] D. Erskine,et al. Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. , 2019, Drug discovery today.
[3] W. Dale Stevens,et al. Meta-analyses of the n-back working memory task: fMRI evidence of age-related changes in prefrontal cortex involvement across the adult lifespan , 2019, NeuroImage.
[4] C. Lustig,et al. Forebrain Cholinergic Signaling: Wired and Phasic, Not Tonic, and Causing Behavior , 2019, The Journal of Neuroscience.
[5] J. V. van Gerven,et al. Reversal of mecamylamine‐induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses , 2018, British journal of clinical pharmacology.
[6] J. Cummings,et al. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease , 2018, Alzheimer's & dementia.
[7] J. Wess,et al. Muscarinic acetylcholine receptors act in synergy to facilitate learning and memory , 2016, Learning & memory.
[8] A. Maelicke,et al. First in human study with a prodrug of galantamine: Improved benefit-risk ratio? , 2016, Alzheimer's & dementia.
[9] J. Uslaner,et al. The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[10] Christian C. Felder,et al. Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus , 2015, Cerebral cortex.
[11] S. Salpeter,et al. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence , 2015, Drugs & Aging.
[12] Anil Kumar,et al. A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.
[13] P. Rossini,et al. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients , 2013, Clinical Neurophysiology.
[14] E. Bullmore,et al. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. , 2013, The international journal of neuropsychopharmacology.
[15] S. Hitchcock,et al. Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist , 2011, Journal of Pharmacology and Experimental Therapeutics.
[16] M. Sabbagh,et al. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease , 2011, Acta Neuropathologica.
[17] Lesley K. Fellows,et al. Lesion Evidence That Two Distinct Regions within Prefrontal Cortex are Critical for n-Back Performance in Humans , 2009, Journal of Cognitive Neuroscience.
[18] F. LaFerla,et al. M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice , 2006, Neuron.
[19] M. Albert,et al. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.
[20] T. Finucane. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. , 2004, Annals of internal medicine.
[21] Nathan Herrmann,et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[22] J. Karlawish,et al. Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies , 2003, Annals of Internal Medicine.
[23] F Barkhof,et al. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.
[24] E. Feigl,et al. Altered cardiovascular responses in mice lacking the M(1) muscarinic acetylcholine receptor. , 2002, The Journal of pharmacology and experimental therapeutics.
[25] M. Wienrich,et al. Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. , 2001, Life sciences.
[26] K. White,et al. Facilitation of Memory Performance by a Novel Muscarinic Agonist in Young and Old Rats , 1999, Pharmacology Biochemistry and Behavior.
[27] W W Offen,et al. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). , 1998, Alzheimer disease and associated disorders.
[28] W W Offen,et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.
[29] N. Cutler,et al. The Safety and Tolerance of Xanomeline Tartrate in Patients with Alzheimer's Disease , 1995, Journal of clinical pharmacology.
[30] E. Perry,et al. Acetylcholine and Hallucinations - Disease-Related Compared to Drug-Induced Alterations in Human Consciousness , 1995, Brain and Cognition.
[31] K. Gough,et al. Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party , 1995 .
[32] D. Mash,et al. Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease , 1995, Journal of neurochemistry.
[33] R. Ihl,et al. Event-related potentials and psychopharmacology. Cholinergic modulation of P300. , 1994, Pharmacopsychiatry.
[34] J. Miller,et al. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. , 1993, Archives of neurology.
[35] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[36] R. Coppola,et al. The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography. , 1991, Archives of neurology.
[37] G. K. Wilcock,et al. Plaques, tangles and dementia A quantitative study , 1982, Journal of the Neurological Sciences.
[38] Brenda Milner,et al. Visually-guided maze learning in man: effects of bilateral hippocampal, bilateral frontal, and unilateral cerebral lesions , 1965 .
[39] Jin-Tai Yu,et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. , 2014, Journal of Alzheimer's disease : JAD.
[40] Christiane,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.
[41] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[42] A. Levey,et al. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. , 1993, Life sciences.